This is not the most recent version of the article. View current version (28 FEB 2014)

Intervention Protocol

Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C

  1. Tahany Awad1,*,
  2. Jesper Brok1,
  3. Kristian Thorlund2,
  4. Goran Hauser3,
  5. Davor Stimac3,
  6. Mahasen Mabrouk4,
  7. Christian Gluud1,
  8. Lise Lotte Gluud1

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 30 JUL 2009

DOI: 10.1002/14651858.CD005441.pub2


How to Cite

Awad T, Brok J, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C, Gluud LL. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD005441. DOI: 10.1002/14651858.CD005441.pub2.

Author Information

  1. 1

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark

  2. 2

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

  3. 3

    Clinical Hospital Centre of Rijeka, Clinics of Internal Medicine - Gastroenterology, Rijeka, Croatia

  4. 4

    Faculty of Medicine, Cairo University, Endemic Medicine Department, Cairo, Egypt

*Tahany Awad, Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. tahany@ctu.rh.dk.

Publication History

  1. Publication Status: Amended to reflect a change in scope (see 'What's new')
  2. Published Online: 7 OCT 2009

SEARCH

This is not the most recent version of the article. View current version (28 FEB 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To systematically evaluate the benefits and harms of pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for patients with chronic hepatitis C.